Navigation Links
EraGens Revolutionary Genomic-Based Technologies

SARS and Cystic Fibrosis detection has been a priority

MADISON, Wis. - EraGen Biosciences of Madison, WI is a pioneering biotechnology company that designs, develops and commercializes genomic-based products and novel nucleic acid technologies. With start-up funding in 1999 from the pharmaceutical firm Novartis and private investors, the company has grown to 32 employees, including......

Full article >>> Ron Leassig, Ph.D., director of the State Laboratory of Hygiene. "Wisconsin has prided itself on being on the forefront of technology when it comes to CF-related screening. This technology will be a major step forward."

With the NIH funding, EraGen is currently using AEGIS to design an automated screening system for CF to be sold to specialized testing laboratories. The State Laboratory o......

Full article >>>
'"/>

Source:wistechnology.com By Jamie Hofmeister 07/31/03


Related biology technology :

1. Merge Technologies net loss doubles to $10.1M
2. Third Wave Technologies to raise $14.9M through private debt
3. Meier joins Broadlook Technologies as COO
4. Platypus Technologies secures $450K SBIR grant
5. Napier joins board of Third Wave Technologies
6. aOva Technologies raises $3 million
7. Linda Weber to run Fiservs Interactive Technologies unit
8. Platypus Technologies receives $1.6 million NIH grant
9. UTEK Corp. acquires Xylose Technologies
10. Platypus Technologies receives Phase 2 grant
11. Cedara acquisition costs hit Merge Technologies numbers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... Jan. 18, 2017 The global biotechnology ... 92.9 billion by 2025, according to a new ... has been adaptive of the function of outsourcing ... 2002. Among the services outsourced, clinical trial management ... Johnson & Johnson was the first pharmaceutical company ...
(Date:1/19/2017)... BD (Becton, Dickinson and Company) (NYSE: BDX ), a ... live webcast of its Annual Meeting of Shareholders on Tuesday, January ... can be accessed from the BD corporate website at http://www.bd.com/investors/ ... ... BD is a global medical technology company that is ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, will feature ... compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, ... . Napabucasin is an orally-administered ... targeting STAT3. i Cancer stem cells (CSCs) possess ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... Clinical Ops Executives 2017 in its continued commitment to the advancement of the ... to discuss current issues related to clinical trial planning and management. , ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/15/2016)... Dec. 14, 2016 "Increase in mobile transactions ... The mobile biometrics market is expected to grow from ... by 2022, at a CAGR of 29.3% between 2016 ... as the growing demand for smart devices, government initiatives, ... "Software component is expected to grow at a ...
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):